Viyash Scientific Ltd
Viyash Scientific Ltd (VIYASH) last reported results for the quarter ended Jun 2026, with sales of ₹946 crore and net profit of ₹79 crore. The stock last traded at ₹234, a market capitalisation of ₹10,331 crore, on a P/E of 46.6. Over the past 52 weeks the stock has ranged between ₹178 and ₹298. Figures are as of 9 Oct 2026 and are not real time.
Viyash Scientific Ltd share price and key metrics
- Current price
- ₹234
- Market cap
- ₹10,331 cr
- Stock P/E
- 46.6
- Book value
- ₹66.6
- ROE
- 7.39%
- ROCE
- 13.4%
- Dividend yield
- 0.00%
- 52w high / low
- 298/178
Metrics as of 9 Oct 2026. Not real time.
Track Viyash Scientific Ltd
Cruxal reads every Viyash Scientific Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Viyash Scientific Ltd growth and returns
- 10 Years
- 19%
- 5 Years
- 20%
- 3 Years
- 34%
- TTM
- 53%
- 10 Years
- 28%
- 5 Years
- 15%
- 3 Years
- 73%
- TTM
- 148%
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- 35%
- 1 Year
- 9%
- 10 Years
- 8%
- 5 Years
- 3%
- 3 Years
- 4%
- Last Year
- 7%
Viyash Scientific Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹946 cr, up 19.4% from ₹792 cr a year earlier. Net profit was ₹79 cr, up 113.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 |
| Expenses | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 |
| Operating profit | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 |
| OPM % | 11% | 13% | 12% | 15% | 20% | 20% | 20% | 19% |
| Other income | 0 | 4 | 1 | 6 | 6 | -27 | 16 | 8 |
| Interest | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 |
| Depreciation | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 |
| Profit before tax | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 |
| Tax % | 20% | -71% | 36% | 24% | 29% | 34% | 47% | 29% |
| Net profit | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 |
| EPS (₹) | 0.10 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Viyash Scientific Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 3,007 | 3,420 | 3,575 |
| Operating profit | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 61 | 387 | 653 | 711 |
| OPM % | 6% | 10% | 12% | 14% | 16% | 8% | 0.8% | 4.5% | 13% | 19% | 20% |
| Net profit | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -30 | 16 | 225 | 267 |
| EPS (₹) | -0.57 | 17.30 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -1.44 | 0.93 | 4.06 | 5.76 |
TTM is the trailing twelve months to the most recent quarter.
Viyash Scientific Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 | 87 |
| Reserves | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 607 | 2,382 | 2,824 |
| Borrowings | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 488 | 654 | 490 |
| Other liabilities | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 389 | 1,042 | 1,195 |
| Total liabilities | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 4,128 | 4,596 |
| Fixed assets | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 2,103 | 2,103 |
| CWIP | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 43 | 70 |
| Investments | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 0 | 0 |
| Other assets | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 922 | 1,981 | 2,422 |
| Total assets | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 4,128 | 4,596 |
As reported by the company. Total assets equal total liabilities by construction.
Viyash Scientific Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7 | 45 | 116 | 115 | 115 | 31 | 17 | 31 | 345 | 323 |
| Cash from investing | -116 | 7 | -68 | -72 | 10 | -94 | -65 | -6 | -448 | -84 |
| Cash from financing | 147 | -57 | -20 | -43 | -139 | 67 | 32 | -1 | 87 | -123 |
| Net cash flow | 24 | -5 | 28 | 0 | -14 | 4 | -16 | 23 | -16 | 115 |
| Free cash flow | -82 | 0 | 92 | 75 | 70 | -1 | -58 | 19 | 258 | 225 |
| CFO / operating profit | 5% | 65% | 92% | 75% | 75% | 52% | 263% | 73% | 102% | 59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Viyash Scientific Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 1% | 40% | 9% | 12% | 16% | 6% | -3% | 0% | 8% | 13% |
| Debtor days | 136 | 111 | 98 | 99 | 93 | 85 | 88 | 89 | 98 | 112 |
| Inventory days | 165 | 125 | 134 | 132 | 139 | 160 | 152 | 166 | 169 | 188 |
| Days payable | 208 | 127 | 141 | 133 | 119 | 119 | 107 | 121 | 121 | 140 |
| Cash conversion cycle | 93 | 110 | 92 | 98 | 112 | 126 | 132 | 135 | 146 | 160 |
| Working capital days | -25 | 20 | 33 | 29 | 51 | 54 | 46 | 30 | 74 | 111 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Viyash Scientific Ltd shareholding pattern
Promoters held 61.31% at Jun 2026, up from 52.61% at Jun 2025. FIIs 4.50% and DIIs 3.76%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.76% | 52.61% | 52.61% | 52.61% | 52.33% | 61.41% | 61.31% | 61.31% |
| FIIs | 6.45% | 6.10% | 6.05% | 6.15% | 5.90% | 3.16% | 2.94% | 4.50% |
| DIIs | 9.99% | 12.01% | 12.82% | 12.98% | 12.91% | 7.36% | 7.98% | 3.76% |
| Public | 30.63% | 29.12% | 28.36% | 28.10% | 28.69% | 27.97% | 27.67% | 30.34% |
| No. of shareholders | 1,54,603 | 1,62,574 | 1,58,152 | 1,47,320 | 1,44,085 | 1,34,194 | 1,27,446 | 1,28,367 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Viyash Scientific Ltd corporate filings
- Viyash Scientific Ltd allots ESOP under Regulation 30 (LODR)Company Updatelow impact
Cruxal's analysis: Viyash Scientific Ltd announced the allotment of Employee Stock Options (ESOP) on October…
Read the full analysis - Certificate under Re. 74(5) of SEBI (DP) Regulation is enclosed.Company Updatelow impact
- Viyash Scientific Limited completes acquisition of BioForLife Italia S.r.l. for EUR 17.0 million, marking strategic expansion into Italy's animal health segmentCompany Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited has finalized the acquisition of 100% of BioForLife Italia…
Read the full analysis - Closure of Trading Window for Q2 FY 2026-27Insider Trading / SASTlow impact
- Viyash Scientific Ltd announces allotment of equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Viyash Scientific Ltd has completed the allotment of equity shares pursuant to the…
Read the full analysis - Viyash Scientific Receives Italian Regulatory Approval for BioForLife Italia S.r.l. AcquisitionCompany Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited has secured the mandatory Italian FDI/Golden Power regulatory…
Read the full analysis - Viyash Scientific Ltd announces allotment of equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Viyash Scientific Ltd has completed the allotment of equity shares pursuant to the…
Read the full analysis - Viyash Scientific Limited: Promoter Entities CA Harbor and CA Hull Divest 5.04 crore Equity Shares via Open MarketInsider Trading / SASThigh impact
Cruxal's analysis: Viyash Scientific Limited has reported a significant stake sale by its promoter entities…
Read the full analysis - Viyash Scientific Reports Strong Q1 FY27 Performance with 20% YoY Revenue Growth and Significant Margin ExpansionCompany Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited delivered a robust Q1 FY27, with revenue from operations…
Read the full analysis - Viyash Scientific Limited releases audio recording of Q1 FY2027 earnings callCompany Updatelow impact
Cruxal's analysis: Viyash Scientific Limited has formally disclosed the audio recording of its earnings…
Read the full analysis - Viyash Scientific Limited Reports Strong Q1 FY27 Financials with 19% Operating MarginCompany Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited (formerly Sequent Scientific Limited) reported robust financial…
Read the full analysis - Viyash Scientific Reports Strong Q1 FY27 Performance with 19.5% Revenue Growth and Strategic Acquisition of Bio For LifeCompany Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited delivered a robust Q1 FY27 performance, reporting revenue of…
Read the full analysis - Viyash Scientific Limited concludes 41st AGM; shareholders approve all resolutions including adoption of new Articles of AssociationAGM/EGMlow impact
Cruxal's analysis: Viyash Scientific Limited has successfully concluded its 41st Annual General Meeting held…
Read the full analysis - Viyash Scientific Limited Concludes 41st Annual General Meeting; Focus Remains on Strategic Growth and Operational PerformanceAGM/EGMlow impact
Cruxal's analysis: Viyash Scientific Limited successfully conducted its 41st Annual General Meeting on…
Read the full analysis - Viyash Scientific Ltd releases Q1 FY 2026-27 press releaseCompany Updatelow impact
Cruxal's analysis: Viyash Scientific Ltd has issued a press release regarding its financial performance for…
Read the full analysis - Viyash Scientific Ltd announces allotment of shares under ESOP Scheme 2026Company Updatelow impact
Cruxal's analysis: Viyash Scientific Limited has executed an allotment of equity shares pursuant to the…
Read the full analysis - Viyash Scientific Reports Q1 FY27 Financials, Approves 400 Crore Debt-to-Equity Conversion for SubsidiaryResulthigh impact
Cruxal's analysis: Viyash Scientific Limited reported Q1 FY27 consolidated revenue of 946.36 crore and a net…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.